Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.

<h4>Background</h4>Nausea and vomiting of pregnancy affects up to 80% of pregnant women, it typically occurs during the first trimester which is the most sensitive time for environmental exposures given organogenesis. Metoclopramide is an antiemetic drug used widely during NVP, but the f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li Sun, Yang Xi, Xiaoke Wen, Wei Zou
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e4663b664c144161b721544dfbb07e7c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e4663b664c144161b721544dfbb07e7c
record_format	dspace
spelling	oai:doaj.org-article:e4663b664c144161b721544dfbb07e7c2021-12-02T20:14:28ZUse of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.1932-620310.1371/journal.pone.0257584https://doaj.org/article/e4663b664c144161b721544dfbb07e7c2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257584https://doaj.org/toc/1932-6203<h4>Background</h4>Nausea and vomiting of pregnancy affects up to 80% of pregnant women, it typically occurs during the first trimester which is the most sensitive time for environmental exposures given organogenesis. Metoclopramide is an antiemetic drug used widely during NVP, but the findings of studies evaluating its safety of use in pregnancy is inconsistent. Therefore, we conducted a systematic review and meta-analysis to assess whether metoclopramide use during first trimester of pregnancy is associated with the risk of major congenital malformations.<h4>Methods</h4>The systematic search using database included Pubmed, Embase, Web of science, and Cochrane library. Studies written in English, comprising with an exposed group and a control group, reporting major congenital malformation as an outcome were included.<h4>Results</h4>Six studies assessing a total number of 33374 metoclopramide-exposed and 373498 controls infants were included in this meta-analysis. No significant increase in the rate of major congenital malformation was detected following metoclopramide use during first trimester (OR, 1.14; 95% CI, 0.93-1.38).<h4>Conclusions</h4>Metoclopramide use during first trimester of pregnancy was not associated with the risk of major congenital malformations.Li SunYang XiXiaoke WenWei ZouPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257584 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Li Sun Yang Xi Xiaoke Wen Wei Zou Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.
description	<h4>Background</h4>Nausea and vomiting of pregnancy affects up to 80% of pregnant women, it typically occurs during the first trimester which is the most sensitive time for environmental exposures given organogenesis. Metoclopramide is an antiemetic drug used widely during NVP, but the findings of studies evaluating its safety of use in pregnancy is inconsistent. Therefore, we conducted a systematic review and meta-analysis to assess whether metoclopramide use during first trimester of pregnancy is associated with the risk of major congenital malformations.<h4>Methods</h4>The systematic search using database included Pubmed, Embase, Web of science, and Cochrane library. Studies written in English, comprising with an exposed group and a control group, reporting major congenital malformation as an outcome were included.<h4>Results</h4>Six studies assessing a total number of 33374 metoclopramide-exposed and 373498 controls infants were included in this meta-analysis. No significant increase in the rate of major congenital malformation was detected following metoclopramide use during first trimester (OR, 1.14; 95% CI, 0.93-1.38).<h4>Conclusions</h4>Metoclopramide use during first trimester of pregnancy was not associated with the risk of major congenital malformations.
format	article
author	Li Sun Yang Xi Xiaoke Wen Wei Zou
author_facet	Li Sun Yang Xi Xiaoke Wen Wei Zou
author_sort	Li Sun
title	Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.
title_short	Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.
title_full	Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.
title_fullStr	Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.
title_full_unstemmed	Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.
title_sort	use of metoclopramide in the first trimester and risk of major congenital malformations: a systematic review and meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/e4663b664c144161b721544dfbb07e7c
work_keys_str_mv	AT lisun useofmetoclopramideinthefirsttrimesterandriskofmajorcongenitalmalformationsasystematicreviewandmetaanalysis AT yangxi useofmetoclopramideinthefirsttrimesterandriskofmajorcongenitalmalformationsasystematicreviewandmetaanalysis AT xiaokewen useofmetoclopramideinthefirsttrimesterandriskofmajorcongenitalmalformationsasystematicreviewandmetaanalysis AT weizou useofmetoclopramideinthefirsttrimesterandriskofmajorcongenitalmalformationsasystematicreviewandmetaanalysis
_version_	1718374676812529664

Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.

Ejemplares similares